ZOTA · NSE
Zota Health Care LImited
₹1,144.5
+2.30% (+₹25.7)
Prev. close
₹1,118.8
Volume
56,557
Delivery %
72.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Zota Health Care LImited
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers pharmaceutical, nutraceutical, ayurvedic, and over-the-counter products. It also provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sujit Paul
Headquarters
Surat
Employees
635
Website
zotahealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹3,963.70 Cr
Dividend yield
0.09%
EPS (TTM)
₹-30.10
Beta (1Y · daily vs NIFTY 50)
1.16
Beta (5Y · monthly vs NIFTY 50)
0.68
Shares float
1.59 Cr
EPS · quarter ended Jun 2026
₹-12.58
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with NSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with NSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹106.79 Cr | ₹131.19 Cr | ₹139.96 Cr | ₹180.49 Cr | ₹292.97 Cr | ₹538.66 Cr | |
| EBITDA | ₹2.91 Cr | ₹16.43 Cr | ₹9.83 Cr | ₹8.71 Cr | ₹-5.47 Cr | ₹17.07 Cr |
| ₹-20.89 L | ₹8.91 Cr | ₹-5.77 Cr | ₹-14.35 Cr | ₹-56.40 Cr | ₹-73.94 Cr | |
| Diluted EPS | ₹-0.09 | ₹3.58 | ₹-2.29 | ₹-5.59 | ₹-20.68 | ₹-22.46 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹85.47 Cr | ₹139.09 Cr | ₹158.11 Cr | ₹228.33 Cr | ₹439.14 Cr | ₹1,131.05 Cr | |
| — | — | ₹45.12 Cr | ₹95.28 Cr | ₹139.60 Cr | ₹270.44 Cr | |
| Stockholders' equity | ₹66.30 Cr | ₹89.63 Cr | ₹80.36 Cr | ₹89.98 Cr | ₹223.68 Cr | ₹693.49 Cr |
Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-88.98 L | ₹13.33 Cr | ₹-2.01 Cr | ₹-5.98 Cr | ₹-49.96 Cr | ₹-84.43 Cr | |
| Investing cash flow | ₹3.82 Cr | ₹-26.65 Cr | ₹14.70 Cr | ₹-12.90 Cr | ₹-92.19 Cr | ₹-313.56 Cr |
| ₹-2.42 Cr | ₹14.27 Cr | ₹-13.88 Cr | ₹18.78 Cr | ₹144.76 Cr | ₹489.94 Cr | |
| Capital expenditure | ₹-1.93 Cr | ₹-3.25 Cr | ₹-12.50 Cr | ₹-16.71 Cr | ₹-45.98 Cr | ₹-112.93 Cr |
| End cash position | ₹1.35 Cr | ₹2.30 Cr | ₹1.12 Cr | ₹1.00 Cr | ₹3.62 Cr | ₹95.57 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Jun 23(5Q) | Jul 23–Sep 23(2Q) | Dec 23–Mar 24(2Q) | Apr 24 | Jun 24 | Aug 24–Sep 24(2Q) | Dec 24 | Feb 25–Mar 25(2Q) | Apr 25 | Jun 25 | Sep 25 | Dec 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.10% | 68.09% | 68.11% | 68.12% | 66.16% | 66.15% | 64.45% | 64.44% | 62.40% | 62.02% | 59.72% | 58.11% | 57.42% | 55.81% | 51.56% | 50.64% | 49.38% |
| Public | 31.90% | 31.91% | 31.89% | 31.88% | 33.84% | 33.85% | 35.55% | 35.56% | 37.60% | 37.98% | 40.28% | 41.89% | 42.58% | 44.19% | 48.44% | 49.36% | 50.62% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Zota Health Care LImited | ₹3,874.69 Cr | ₹1,118.8 | — | 5.59 | -10.7% | 0.39 | +83.9% | -23.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Zota Health Care monitors utilisation of Rs 34,033.24 lakh funds from QIP
Zota Health Care Limited's monitoring agency report for Q1 2026 detailed the utilization of Rs 34,033.24 lakh from its Qualified Institutional Placement. Funds were allocated to working capital, new store investments, and general corporate purposes, with remaining unutilized funds held in fixed deposits. CRISIL Ratings confirmed no deviations from the QIP's stated objectives.
Zota Health's Davaindia Network crosses 2,825 stores as revenue jumps 68% in Q1 FY27
Zota Health Care Limited reported a 68% jump in Q1 FY27 revenue, driven by its Davaindia network expanding to 2,825 stores. Despite strong sales growth, EBITDA turned negative due to costs associated with rapid store expansion. The company indicated a slower pace of store additions for the next quarter.